You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》生物製藥公司科倫博泰(06990.HK)明日起招股 入場費7,353.4元
默沙東任第二大股東的生物製藥公司科倫博泰(06990.HK)公布來港上市計劃,擬於全球發行2,244.61萬股H股,當中國際配售部分佔九成,餘下一成於本地公開發售。每股招股價介乎60.6至72.8元,集資最多約16.34億元。 每手100股H股入場費為約7,353.42元,招股期由明日(29日)起,至下周二(7月4日)中午截止,預期同日定價,並於7月11日掛牌,由高盛及中信証券擔任聯席保薦人。 是次招股引入5名基石投資者,合共認購逾6,728.36萬美元等值股份,當中母公司科倫藥業(002422.SZ)旗下科倫國際將投資逾2,933.1萬美元,而RTW Funds、Laurion Capital Master Fund、TruMed,以及東方證券(03958.HK)與中國東航集團有份投資的匯添富,將各自認購1,500萬美元、728.6萬美元、728.6萬美元及6,000萬元人民幣等值股份。 以招股價中位數每股66.7元計,集資淨額約13.75億元,所得款項淨額約45%用於核心產品SKB264及A166的研發及商業化;約30%將用於其他主要產品的研發及商業化;約12%擬用於為持續開發技術平台、推進其他現有管線資產及探索開發新候選藥物;約8%將用於擴充產能及質量控制系統;剩餘約5%為營運資金及其他一般用途。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account